Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: Part B - Behavioral results

James Adams, Matthew Baral, Elizabeth Geis, Jessica Mitchell, Julie Ingram, Andrea Hensley, Irene Zappia, Sanford Newmark, Eva Gehn, Robert A. Rubin, Ken Mitchell, Jeff Bradstreet, Jane El-Dahr

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background: This study investigated the effects of oral dimercapto succinic acid (DMSA) therapy on the behavioural symptoms of children with autism spectrum disorders (ASD) ages 3-8 years. Methods: Phase 1 involved 65 children with ASD who received one round of DMSA (3 days). Participants who had high urinary excretion of toxic metals were selected to continue on to phase 2. In phase 2, 49 participants were randomly assigned in a double-blind design to receive an additional 6 rounds of either DMSA or placebo. Results: The groups receiving one round and seven rounds of DMSA had significant improvements on all the assessment measures. For the seven round group, the degree of improvement on the assessment measures could be partially explained by a regression analysis based on excretion of toxic metals and changes in glutathione (adjusted R2 of 0.28-0.75, p < 0.02 in all cases). One round of DMSA had nearly the same benefit as seven rounds. The assessment measures correlated reasonably with one another at the beginning of the study (r = 0.60-0.87) and even better at the end of the study (r = 0.63-0.94). Conclusion: Overall, both one and seven rounds of DMSA therapy seems to be reasonably safe in children with ASD who have high urinary excretion of toxic metals, and possibly helpful in reducing some of the symptoms of autism in those children.

Original languageEnglish (US)
Pages (from-to)17
Number of pages1
JournalBMC Clinical Pharmacology
Volume9
DOIs
StatePublished - Oct 23 2009

Fingerprint

Succinic Acid
Safety
Poisons
Metals
Therapeutics
Behavioral Symptoms
Autistic Disorder
Glutathione
Autism Spectrum Disorder
Placebos
Regression Analysis

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders : Part B - Behavioral results. / Adams, James; Baral, Matthew; Geis, Elizabeth; Mitchell, Jessica; Ingram, Julie; Hensley, Andrea; Zappia, Irene; Newmark, Sanford; Gehn, Eva; Rubin, Robert A.; Mitchell, Ken; Bradstreet, Jeff; El-Dahr, Jane.

In: BMC Clinical Pharmacology, Vol. 9, 23.10.2009, p. 17.

Research output: Contribution to journalArticle

Adams, J, Baral, M, Geis, E, Mitchell, J, Ingram, J, Hensley, A, Zappia, I, Newmark, S, Gehn, E, Rubin, RA, Mitchell, K, Bradstreet, J & El-Dahr, J 2009, 'Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: Part B - Behavioral results', BMC Clinical Pharmacology, vol. 9, pp. 17. https://doi.org/10.1186/1472-6904-9-17
Adams, James ; Baral, Matthew ; Geis, Elizabeth ; Mitchell, Jessica ; Ingram, Julie ; Hensley, Andrea ; Zappia, Irene ; Newmark, Sanford ; Gehn, Eva ; Rubin, Robert A. ; Mitchell, Ken ; Bradstreet, Jeff ; El-Dahr, Jane. / Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders : Part B - Behavioral results. In: BMC Clinical Pharmacology. 2009 ; Vol. 9. pp. 17.
@article{170a806b2f2f4f0ba3cc37ebe712c68d,
title = "Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: Part B - Behavioral results",
abstract = "Background: This study investigated the effects of oral dimercapto succinic acid (DMSA) therapy on the behavioural symptoms of children with autism spectrum disorders (ASD) ages 3-8 years. Methods: Phase 1 involved 65 children with ASD who received one round of DMSA (3 days). Participants who had high urinary excretion of toxic metals were selected to continue on to phase 2. In phase 2, 49 participants were randomly assigned in a double-blind design to receive an additional 6 rounds of either DMSA or placebo. Results: The groups receiving one round and seven rounds of DMSA had significant improvements on all the assessment measures. For the seven round group, the degree of improvement on the assessment measures could be partially explained by a regression analysis based on excretion of toxic metals and changes in glutathione (adjusted R2 of 0.28-0.75, p < 0.02 in all cases). One round of DMSA had nearly the same benefit as seven rounds. The assessment measures correlated reasonably with one another at the beginning of the study (r = 0.60-0.87) and even better at the end of the study (r = 0.63-0.94). Conclusion: Overall, both one and seven rounds of DMSA therapy seems to be reasonably safe in children with ASD who have high urinary excretion of toxic metals, and possibly helpful in reducing some of the symptoms of autism in those children.",
author = "James Adams and Matthew Baral and Elizabeth Geis and Jessica Mitchell and Julie Ingram and Andrea Hensley and Irene Zappia and Sanford Newmark and Eva Gehn and Rubin, {Robert A.} and Ken Mitchell and Jeff Bradstreet and Jane El-Dahr",
year = "2009",
month = "10",
day = "23",
doi = "10.1186/1472-6904-9-17",
language = "English (US)",
volume = "9",
pages = "17",
journal = "BMC Clinical Pharmacology",
issn = "1472-6904",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders

T2 - Part B - Behavioral results

AU - Adams, James

AU - Baral, Matthew

AU - Geis, Elizabeth

AU - Mitchell, Jessica

AU - Ingram, Julie

AU - Hensley, Andrea

AU - Zappia, Irene

AU - Newmark, Sanford

AU - Gehn, Eva

AU - Rubin, Robert A.

AU - Mitchell, Ken

AU - Bradstreet, Jeff

AU - El-Dahr, Jane

PY - 2009/10/23

Y1 - 2009/10/23

N2 - Background: This study investigated the effects of oral dimercapto succinic acid (DMSA) therapy on the behavioural symptoms of children with autism spectrum disorders (ASD) ages 3-8 years. Methods: Phase 1 involved 65 children with ASD who received one round of DMSA (3 days). Participants who had high urinary excretion of toxic metals were selected to continue on to phase 2. In phase 2, 49 participants were randomly assigned in a double-blind design to receive an additional 6 rounds of either DMSA or placebo. Results: The groups receiving one round and seven rounds of DMSA had significant improvements on all the assessment measures. For the seven round group, the degree of improvement on the assessment measures could be partially explained by a regression analysis based on excretion of toxic metals and changes in glutathione (adjusted R2 of 0.28-0.75, p < 0.02 in all cases). One round of DMSA had nearly the same benefit as seven rounds. The assessment measures correlated reasonably with one another at the beginning of the study (r = 0.60-0.87) and even better at the end of the study (r = 0.63-0.94). Conclusion: Overall, both one and seven rounds of DMSA therapy seems to be reasonably safe in children with ASD who have high urinary excretion of toxic metals, and possibly helpful in reducing some of the symptoms of autism in those children.

AB - Background: This study investigated the effects of oral dimercapto succinic acid (DMSA) therapy on the behavioural symptoms of children with autism spectrum disorders (ASD) ages 3-8 years. Methods: Phase 1 involved 65 children with ASD who received one round of DMSA (3 days). Participants who had high urinary excretion of toxic metals were selected to continue on to phase 2. In phase 2, 49 participants were randomly assigned in a double-blind design to receive an additional 6 rounds of either DMSA or placebo. Results: The groups receiving one round and seven rounds of DMSA had significant improvements on all the assessment measures. For the seven round group, the degree of improvement on the assessment measures could be partially explained by a regression analysis based on excretion of toxic metals and changes in glutathione (adjusted R2 of 0.28-0.75, p < 0.02 in all cases). One round of DMSA had nearly the same benefit as seven rounds. The assessment measures correlated reasonably with one another at the beginning of the study (r = 0.60-0.87) and even better at the end of the study (r = 0.63-0.94). Conclusion: Overall, both one and seven rounds of DMSA therapy seems to be reasonably safe in children with ASD who have high urinary excretion of toxic metals, and possibly helpful in reducing some of the symptoms of autism in those children.

UR - http://www.scopus.com/inward/record.url?scp=84869091508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869091508&partnerID=8YFLogxK

U2 - 10.1186/1472-6904-9-17

DO - 10.1186/1472-6904-9-17

M3 - Article

C2 - 19852790

AN - SCOPUS:70450280618

VL - 9

SP - 17

JO - BMC Clinical Pharmacology

JF - BMC Clinical Pharmacology

SN - 1472-6904

ER -